- Home
- DNTH vs CCAP Comparison
DNTH vs CCAP Comparison
Compare DNTH & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- CCAP
- Stock Information
- Founded
- DNTH 2015
- CCAP 2015
- Country
- DNTH United States
- CCAP United States
- Employees
- DNTH N/A
- CCAP N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- CCAP Finance: Consumer Services
- Sector
- DNTH Health Care
- CCAP Finance
- Exchange
- DNTH Nasdaq
- CCAP Nasdaq
- Market Cap
- DNTH 565.7M
- CCAP 537.8M
- IPO Year
- DNTH N/A
- CCAP N/A
- Fundamental
- Price
- DNTH $19.50
- CCAP $15.50
- Analyst Decision
- DNTH Strong Buy
- CCAP Strong Buy
- Analyst Count
- DNTH 8
- CCAP 5
- Target Price
- DNTH $54.33
- CCAP $18.90
- AVG Volume (30 Days)
- DNTH 418.5K
- CCAP 203.0K
- Earning Date
- DNTH 05-08-2025
- CCAP 05-07-2025
- Dividend Yield
- DNTH N/A
- CCAP 1.29%
- EPS Growth
- DNTH N/A
- CCAP N/A
- EPS
- DNTH N/A
- CCAP 1.99
- Revenue
- DNTH $6,235,000.00
- CCAP $197,363,000.00
- Revenue This Year
- DNTH N/A
- CCAP N/A
- Revenue Next Year
- DNTH N/A
- CCAP N/A
- P/E Ratio
- DNTH N/A
- CCAP $7.80
- Revenue Growth
- DNTH 120.63
- CCAP 7.18
- 52 Week Low
- DNTH $13.37
- CCAP $13.54
- 52 Week High
- DNTH $32.27
- CCAP $20.19
- Technical
- Relative Strength Index (RSI)
- DNTH 53.31
- CCAP 41.35
- Support Level
- DNTH $18.37
- CCAP $14.05
- Resistance Level
- DNTH $19.76
- CCAP $15.32
- Average True Range (ATR)
- DNTH 1.93
- CCAP 0.79
- MACD
- DNTH 0.45
- CCAP -0.01
- Stochastic Oscillator
- DNTH 95.93
- CCAP 53.19
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.